ArticleKidney international reports2026
Implementing Kidney Disease: Improving Global Outcomes 2024 Through Laboratory-Estimated GFR Across Ages.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic kidney disease (CKD) represents a major public health issue, with early detection depending on accurate estimation of glomerular filtration rate (GFR). The 2024 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend age-adapted equations, whereas the 2009 CKD Epidemiology Collaboration (CKD-EPI) equation remains widely used in Europe despite its inapplicability in children and uncertain performance in young adults and the elderly. The objectives of this study were to compare the European Kidney Function Consortium (EKFC) and 2009 CKD-EPI equations for estimated GFR (eGFR)-based CKD staging in a general population (PCrAGE substudy), and to evaluate their performance against measured GFR (mGFR) in a reference cohort (mGFR substudy). Methods: We analyzed data from 30,104 individuals aged 2 to 99 years with plasma creatinine (PCr) available (PCrAGE). eGFR was calculated using EKFC (all ages), CKD-EPI (adults), and Berlin Initiative Study 1 (BIS1, aged > 70 years). Performance was tested in 4144 mGFR measurements using bias and P30 across age groups and CKD stages. Results: In PCrAGE, switching from CKD-EPI to EKFC impacted CKD staging (3.2% from stage II to III; 0.4% from stage III tp IV). In the mGFR cohort, all equations showed declining accuracy with advancing CKD stage. EKFC consistently had the lowest bias and highest P30 in adults. CKD-EPI performed poorly in young adults (aged 18-25 years), showing substantial positive bias (∼20 ml/min per 1.73 m Conclusion: EKFC provides a continuous and robust equation for eGFR estimation across the lifespan, offering an advantage over CKD-EPI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.